Member Info for davidpqz

Agreed PC01. The sp went to £3 on less substantial news than this !

Marve, this isn't a football match. FFS try to maintain some objectivity. It may save you some money. I sometimes despair of these BB's. Shouting loudly what you want to hear does not make it true. The figures quoted are from GDR RNS's.

Very solid results . No sign of the effect wearing off. Increasing the dose to two million stem cells may improve them even further.

The GDR test is not 100% accurate. The terms used are sensitivity and specificity.

Sensitivity is the percentage of people with the disease who get detected by the test and in GDR's case this is 100%.
Specificity is the percentage of people who are healthy who get identified as healthy. In GDR's case this is 98.2%.
In a population of 10,000 where 1% (I.e.100) have the disease, the GDR test will correctly identify all those who have the disease but it will also identify 178.2 who do not have the disease as having the disease. However if it says you haven't got it, you haven't got it – all 9,721.8 of you which obviously saves a lot of extra testing.

There is a company in the US Quidel which has a 15 minute point of care test. On the face of it this is ideal – no lab involvement and an immediate result. Sadly for them, their sensitivity is only 80% which means that 1 in five with the disease is being missed and being released into the population to reinfect. Clearly GDR has the better problem but it is not correct to say that it is 100% accurate.

The 7,100,000 shares reported today are the shares from the conversion of the convertible bond announced on the 16th. Nobody bought any shares.

In his recent presentation (below) the CEO says that the challenge is to compress a product development life cycle which normally takes 18 months to two years into a matter of weeks. Does anyone have any idea of how they're going to do this?
Also I see in the AIMChaos blog that the author thinks that phase 1 trials will be inflection points. A phase 1 trial is concerned with safety i.e. that the treatment doesn't poison or otherwise harm the patient. It is not concerned with efficacy and the doses initially administered are tiny. It usually takes years to get to a phase 3 trials, approvals and to market.
I know I will receive a lot of abuse for making these points but there is a lot of highly excited hot air on this BB and I'm afraid some people have already been sucked in by it.
https://avacta.com/how-diagnostic-test-performance-is-measured/

Nuts

A lot of you need to take a cold shower.

Why?

The original news item on their website re the swab test appears to have been deleted. They are just about to start a four week trial using saliva. Personally, I think the message that you quote indicates that they don't really have an advantage over a standard PCR test.

Hants. My virus protection really hates that link ! Have you got a better one?

Wasn't it due at the end of May? And is there any news on the the sensitivity and specificity of the test?

Meaning what goes up must come down? I prefer hyperbolic myself. To infinity and beyond !

Apologies, Blustington is quite right, the dilution was last week not tomorrow - I was looking at the pre dilution figures. Thanks to all you **** for your well considered and articulate opinions. May you get lucky.

GDR burns about 8-10m cash each year. It currently has about 3.8m in the bank. Sales from neonatal hearing loss test will not hit the bank until late this year at the earliest. Sales of the Covid test will start coming in next month. This share has a lot of enthusiastic followers as evidenced by the rise from @10p to over 100p. Now, if you were an ambitious CEO wanting to speed up your development projects you would probably start looking for more investment . You could go to the banks or the bond market but one day you would have to pay it back. Meanwhile you have a lot of followers who believe you can walk on water - so why not tap them for a few million quid? AVACTA did it recently to fund some very worthwhile projects so why not here?

Just saying.

Very encouraging, especially in the final minutes when he talks of being in the end game.
By the way, it's really nice to enjoy the thoughtful, well informed comments here. Avacta by contrast is a complete madhouse !

Optigene trials in Hampshire hospitals are due to end at the start of July.
We haven't yet started any clinical trials.
The AVCT CEO said "“We are going to develop, clinically validate and get the regulatory approvals for that test and make it commercially available as quickly as we can over the summer for both health care professionals and consumers.”
Be very careful if you are thinking of commiting money that you can't afford to lose because it doesn't look like we will be first to market.
Note also that the news which should be announced shortly is for a PROTOTYPE device.

The potential has been there since last year's various announcements. Why today?

The Greek Dichem deal is just a dealership deal just like the ones with Japan and Italy. Proactive have just reported it today but I don't think that warrants a 60% rise. Good news tomorrow??

I've been thinking that this could be used in a mutually beneficial way if we formed a thread for people interested in serious research which we could share. To make it manageable we could filter out the legions of idiots who infest this place.